Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesBruce Neal, David R. Matthews, Vlado Perkovic et al.|New England Journal of Medicine|2017Cited by 7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Meg Jardine et al.|New England Journal of Medicine|2019Cited by 6k
Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Vlado Perkovic, Toshiharu Ninomiya et al.|The Lancet|2015Cited by 2.3k
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisXinfang Xie, Anthony Rodgers, Emily Atkins et al.|The Lancet|2015Cited by 984
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Doreen Zhu et al.|The Lancet|2022Cited by 969